Stock Report

Download full stock data and analysis for free Last Updated: 05-Sep-2026

Stock Rating

Is this stock worth it? Our ratings reveal the truth.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Clear All

Gracell Biotechnologies (GRCL) Key Ratios

Stock Card factsheet share-fund-plan-icon

$10.25

$0.00 (0.00%)

As on 22-Feb-2024 09:30EDT

Market cap

info icon

$990 Mln

Revenue (TTM)

info icon

$0 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

4.4

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue -- -- -- -- --
EBIT 13.74 28.29 5.96 -206.69 --
Net Profit 53.98 60.73 17.44 -196.71 --
EPS 62.56 68.33 24.39 5.83 --
Book Value -- -- -26.85 -31.94 --
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMDec-22Dec-21
EBIT-Margin info -126,659.29-------126,659.29
Net Margin info ----------
Return on equity info -36.60---35.10-37.93-35.20
Return on Capital info -32.11-----34.31-32.07
Return on Assets info -30.71---23.64-32.69-30.80
Debt to Equity (x) info ----0.020.130.08

Profitability

View Detailed Peer Comparison

ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Gracell Biotechnologies (GRCL)
--
-34.31
-32.07
-29.95
-49.40
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

-35.10

Higher than Peers by 5.30

Profit after tax / Average Net worth * 100

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Gracell Biotechnologies (GRCL)
-35.10
-37.93
-35.20
-36.68
-102.57
Peer Median
-40.40
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

-23.64

Higher than Peers by 7.34

Profit after tax / Average Total assets * 100

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Gracell Biotechnologies (GRCL)
-23.64
-32.69
-30.80
-28.63
-47.14
Peer Median
-30.98
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

--

--

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Gracell Biotechnologies (GRCL)
--
--
-126,659.29
--
--
Peer Median
-83.62
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

--

--

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Gracell Biotechnologies (GRCL)
--
--
-127,289.62
--
--
Peer Median
-92.67
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

Revenue Growth

--

--

Year on year growth in net sales

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Gracell Biotechnologies (GRCL)
--
-1.00
--
--
--
Peer Median
53.95
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

5.96

Higher than Peers by 6.76

Year on year growth in operating profit (EBIT)

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Gracell Biotechnologies (GRCL)
5.96
-29.59
-121.02
-43.09
-141.11
Peer Median
-0.80
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

17.44

Higher than Peers by 24.74

Year on year growth in profit after tax

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Gracell Biotechnologies (GRCL)
17.44
-30.40
-136.29
-49.17
-117.42
Peer Median
-7.30
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

24.39

Higher than Peers by 9.74

Year on year growth in earnings per share

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Gracell Biotechnologies (GRCL)
24.39
-0.27
-1.19
0.90
-19.29
Peer Median
14.65
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

-14.38

Lower than Peers by 4.20

Year on year growth in book value per share

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Gracell Biotechnologies (GRCL)
-14.38
--
--
--
--
Peer Median
-10.18
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

0.02

--

Total debt / Net worth

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Gracell Biotechnologies (GRCL)
0.02
0.13
0.08
0.13
0.54
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

0.05

--

(Short term borrowings / Net worth)

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Gracell Biotechnologies (GRCL)
0.05
0.09
0.05
0.06
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

7.73

Higher than Peers by 1.92

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Gracell Biotechnologies (GRCL)
7.73
6.78
12.15
8.73
18.74
Peer Median
5.81
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

7.73

Higher than Peers by 2.04

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Gracell Biotechnologies (GRCL)
7.73
6.90
12.10
9.07
18.22
Peer Median
5.70
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

-76.15

Lower than Peers by 74.06

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Gracell Biotechnologies (GRCL)
-76.15
-89.17
-91.56
-97.33
--
Peer Median
-2.09
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

--

--

Debtors outstanding / Net Sales * 100

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Gracell Biotechnologies (GRCL)
--
--
11,117.49
--
--
Peer Median
19.14
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

--

--

Sales / Average Total Assets

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Gracell Biotechnologies (GRCL)
--
--
0.00
--
--
Peer Median
0.06
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Gracell Biotechnologies (GRCL)
--
--
35,752.09
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...